Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma

Inclusion Criteria

• •Histologically confirmed diagnosis of RCC
• •Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
• •Metastatic Measurable disease, as defined by RECIST 1.1
• •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
• •Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
• •Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
• •Hematological:
• •* Absolute neutrophil count ≥ 1.5 × 109/L
• •* Platelets ≥ 100 × 109/L
• •* Hemoglobin≥ 9.0 g/dL
• •Renal:
• •* Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min
• •Hepatic:
• •* Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled)
• •* Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)